ORIG3N

UnDx Consortium to focus on precision medicine

Tuesday, August 16, 2016

UnDx Consortium has launched. This organization brings together five precision medicine technology providers and experts from medical centers and universities across the country to collaborate in an effort to produce new hypotheses for a set of six patients struggling with undiagnosed diseases. UnDx Consortium will explore results of cutting-edge tests analyzing samples from these patients and their families.

[Read More]

ORIG3N adds Melissa May as VP of product strategy

Friday, May 20, 2016

ORIG3N, a pioneer in the field of regenerative medicine, has added Melissa May as the company’s vice president of product strategy to establish partnerships and collaborations to bring in non-dilutive funding that will support R&D to develop future product offerings. In addition, May will play a role in the strategy and channel development of ORIG3N’s life science products, as well as LifeProfiles, which are genetic analysis available for consumers.

[Read More]

Orig3n, Sharp Edge Labs ink drug discovery alliance

Monday, March 28, 2016

ORIG3N, a regenerative medicine provider, and Sharp Edge Labs, a drug discovery and development company focused on genetic disorders, have entered into a drug discovery alliance. As part of the alliance, ORIG3N will make patient-derived cells available to Sharp Edge Labs for use in their drug discovery platform for genetic disorders.

[Read More]

ORIG3N, LabCorp collaborate

Wednesday, May 27, 2015

ORIG3N, a Boston-based biotechnology company, is collaborating with Laboratory Corporation of America Holdings (LabCorp), a healthcare diagnostics company. LabCorp has invested in ORIG3N and will provide storage for LifeCapsule, ORIG3N’s induced pluripotent stem cell (iPSC) storage, at its biorepository facilities as well as perform genetic testing on the stored cells. LabCorp’s experience will help to accelerate the development of LifeCapsule’s specimen repository. 

[Read More]